PACS Group Q4 2025 Earnings Call Summary

1Key Financial Results and Metrics

Q4 2025 Revenue: $1.36 billion, a 12% increase year-over-year.

Q4 Net Income: $59.8 million.

Q4 Adjusted EBITDAR: $237.7 million.

Q4 Adjusted EBITDA: $142.1 million.

Full Year 2025 Revenue: $5.29 billion, up 29% from 2024.

Full Year Net Income: $191.5 million; diluted EPS of $1.22.

Full Year Adjusted EBITDAR: $883.9 million; Adjusted EBITDA: $505 million.

Average Occupancy: 89.1% for the year; mature facilities at 94.9%.

Net Leverage: Approximately 0.3x, indicating a strong balance sheet.

2Strategic Updates and Business Highlights

PACS executed 8 strategic acquisitions in 2025, enhancing market density and local scale.

The company operates 321 facilities across 17 states, serving over 31,700 patients daily.

Focused on integrating and optimizing the expanded portfolio, with positive trends in quality ratings and occupancy.

73.4% of skilled nursing facilities rated 4 or 5 stars by CMS, with an average star rating of 4.4.

Continued investment in leadership development through the Administrator in Training (AIT) program, with 38 participants currently.

3Forward Guidance and Outlook

2026 Revenue Guidance: Expected between $5.65 billion to $5.75 billion, representing an 8% growth over 2025.

2026 Adjusted EBITDA Guidance: Expected between $555 million to $575 million, with a midpoint of $565 million, indicating nearly 12% growth.

The outlook is based on steady organic growth, improved occupancy, and disciplined capital allocation.

4Challenges and Points of Concern

Ramping facilities saw a decline in occupancy to 86.3% from over 93% the previous year, reflecting the transition of facilities into ramping status.

New facilities averaged 81.1% occupancy, down from 82.8% in 2024, indicating ongoing stabilization challenges.

Pricing for acquisitions has increased due to inflation and rising real estate costs, though there are signs of stabilization in the market.

5Notable Q&A Insights

Payer Conversations: The company is well-positioned to negotiate favorable contracts as facilities improve quality metrics, enhancing attractiveness to insurers.

M&A Pipeline: PACS aims to acquire about 5 facilities per quarter in 2026, with a robust pipeline of potential deals.

De Novo Activity: While acquisitions remain the primary growth strategy, PACS is open to de novo projects if they align with strategic goals.

Value-Based Purchasing: The company feels confident about adapting to new reimbursement models tied to quality metrics, viewing it as an opportunity rather than a risk. Overall, PACS Group demonstrated strong financial performance in 2025, with a focus on strategic growth through acquisitions and operational excellence, while facing challenges related to occupancy in ramping facilities and rising acquisition costs. The outlook for 2026 remains optimistic, supported by a solid balance sheet and ongoing improvements in quality metrics.